The open artery hypothesis: Past, present, and future

Journal of Thrombosis and Thrombolysis

Volumn 5, Issue 2, 1998, Pages 101-112

  Gael, Mukesh ^a   Theodore Dodge Jr , J ^a   Rizzo, Michael ^a   McLean, Christine ^a   Ryan, Kathryn A ^a   Daley, William L ^a   Cannon, Christopher P ^a   Michael Gibson, C ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANISTREPLASE; FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE;

ACUTE HEART INFARCTION; BLOOD CLOT LYSIS; CLASSIFICATION; CORONARY ARTERY BLOOD FLOW; FIBRINOLYTIC THERAPY; HUMAN; HYPOTHESIS; INTRACARDIAC DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; PRIORITY JOURNAL; RECANALIZATION; REVIEW; TECHNIQUE; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0031932346     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008817810451     Document Type: Review

References (83)

1. Blumgart HL, Gilligan R, Schlesinger MJ. Experimental studies on the effect of temporary occlusion of coronary arteries. The production of myocardial infarction. Am Heart 1941;22:374-389.
2. Maroko PR, Braunwald E. Modification of myocardial infarction size after coronary occlusion. Ann Intern Med 1973;79:720-733.
3. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. Myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation 1977;56:786-794.
4. Rentrop KP, Blanke H, Karsch KR, Kreuzer H. Initial experience with transluminal recanalization of the occluded infarct related artery in acute myocardial infarction. Comparison with conventionally treated patients: Clin Cardiol 1979;2:92-102.
5. Gibson CM, Marble SJ, McCabe CH, Cannon CP for the TIMI 4 Study Group. Injections prior to 90 minutes following thrombolysis do not affect patency. Circulation 1995;92:I531-I532.
6. Kloner RA, Alker KJ. The effect of streptokinase on intramyocardial hemorrhage, infarct size, and the no-reflow phenomenon during coronary reperfusion. Circulation 1984;70:513-521.
7. Hodgson, J. Mancini GBJ, LeGrand V, Vogel RA. Characterization of changes in coronary blood flow during the first six seconds after intracoronary contrast injection. Invest Radiol 1985;20:246-252.
8. Hwang MH, Piao ZE, Murdock DK, Messmore H, Giardina JJ, Scanlon PJ. Risk of thromboembolism during diagnostic and interventional cardiac procedures with nonionic contrast media. Radiology 1990;174:453-457.
9. Gasperetti CM, Feldman MD, Burwell LR, et al. Influence of contrast media on thrombus formation during coronary angioplasty. J Am Coll Cardiol 1991; 18:443-450.
10. The TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med 1985;31:932-936.
11. Verstraete M, Bernard R, Bory M. Randomized trial of intravenous streptokinase in acute myocardial infarction: Report from the European Cooperative Study Group for recombinant tissue type plasminogen activator. Lancet 1985;1:842-847.
12. Gruppo Italiano per lo Studio dell Sopravvivenza nell Infarcto Miocardico. GISSI-2: A factorial randomized trial of alteplase versus streptokinase and heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
13. Third International Study of Infarct Survival Collaborative Group. ISIS-3: A randomized comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,229 cases of suspected acute myocardial infarction. Lancet 1992; 339:753-770.
14. Weaver WD, Cerque M, Hallstrom AP, et al. and the Myocardial Infarction Trial and Intervention Project Group. Pre-hospital initiated vs. hospital initiated thrombolytic therapy. Myocardial Infarction Triage and Intervention Trial. JAMA 1990;270:1211-1216.
15. The European Myocardial Infarction Project (EMIP) Group. Pre-hospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993;329:383-389.
16. Neuhaus KL, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989;14:1566-1569.
17. Gemmel JD, Hogg KJ, MacIntyre PD, Booth N, Rae AP, Dunn FG, Hillis WS. A pilot study of efficacy and safety of bolus administration of alteplase in acute myocardial infarction. Br Heart J 1991;66:134-138
18. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
19. The GUSTO Angiographie Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329:1615-1622.
20. Vogt A, von Essen R, Tebbe U, Feuerer W, Appel KF, Neuhaus KL. Impact of early perfusion status of the infarctrelated artery on short-term mortality after thrombolysis for acute myocardial infarction: Retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993;21:1391-1395.
21. Braunwald E. The open artery theory is alive and well-again. N Engl J Med 1993;329:1650-1652.
22. Karagounis L, Sorensen SG, Menlove RL, Moreno F, Anderson JL for the TEAM-2 Investigators. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. J Am Coll Cardiol 1992;19:1-10.
23. Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL for the TEAM-3 Investigators. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 study. Circulation 1993;87:1829-1839.
24. Lincoff AM, Ellis SG, Galeana A, Sigmon KN, Lee KL, Rosenschein U, and the TAMI Study Group. Is a coronary artery with TIMI grade 2 flow "patent"? Outcome in the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial. Circulation 1992;86:I268.
25. Gibson CM, Cannon CP, Piana RN, et al. Angiographie predictors of early reocclusion in the TIMI 4 trial. J Am Coll Cardiol 1995;25:582-589.
26. Andreotti F, Pasceri V, Hackett D, Davies G, Haider A, Maseri A. Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction. N Engl J Med 1996;334:7-12.
27. Kloner RA, Shook TS, Przyklenk K, et al. for the TIMI 4 Investigators. Previous angina alters in hospital outcome in TIMI 4: A clinical correlate to preconditioning? Circulation 1993;88:I49.
28. Jang IK, Gold HK, Ziskind AA, et al. Differential sensitivity of erythrocyte rich and platelet rich arterial thrombi to lysis with recombinant tissue plasminogen activator: A possible explanation for resistance to coronary thrombolysis. Circulation 1989;79:920-928.
29. Cannon CP, McCabe CH, Diver DJ, et al. and The TIMI 4 Investigators. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol 1994; 24:1602-1610.
30. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators. Circulation 1995;91:2725-2732.
31. Benedict CR, Refino CJ, Keyt BA, Pakala R, Paoni NF, Thomas R, Bennett WF. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human tPA. Circulation 1995;92:3032-3040.
32. Vanderschueren S, Stockx L, Wilms G, Lacroix H, Verhaeghe J, Collen D. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase. Circulation 1995;92:2050-2057.
33. Topol EJ. Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa inhibitors. Am Heart J 1995; 130:666-672.
34. Ellis SG, Suva ER, Heyndrickx G, et al. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute myocardial infarction. Circulation 1994;90:2280-2284.
35. Gibson CM, Cannon CP, Piana RN, et al. for the TIMI 4 Investigators. Rescue PTCA in the TIMI 4 trial. J Am Coll Cardiol 1994:225.
36. Califf RM, O'Neill W, StackRS, et al. Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. Ann Intern Med 1988; 108:658-62.
37. Kwon K, Freedman B, Wilcox I, et al. The unstable ST segment early after thrombolysis for acute myocardial infarction and its usefulness as a marker of recurrent coronary occlusion. Am J Cardiol 1991;67:109-115.
38. Laperche T, Steg PG, Hanssen M. A study of biochemical markers of reperfusion early after thrombolysis for acute myocardial infarction. The PERM study group. Prospective evaluation of reperfusion markers. Circulation 1995; 92:2079-2086.
39. Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987;317:581-588.
40. The TIMI Research Group. Immediate versus delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. JAMA 1988; 260:2849-2858.
41. Simons ML, Col J, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988;1:197-203.
42. Califf RM, Topol EJ, Stack RS, et al. An evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction: The TAMI 5 randomized trial. Circulation 1991;83:1543-1556.
43. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) phase II trial. N Engl J Med 1989;320:618-627.
44. Grines CL, Browne KF, Marco J, et al. for the Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:685-691.
45. DeBoer MJ, Hoorntje JCA, Ottervenger JP, et al. Immediate coronary angioplasty versus intravenous streptokinase in acute myocardial infarction: Left ventricular ejection fraction, hospital mortality and reinfarction. J Am Coll Cardiol 1994;23:1004-1008.
46. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993;328:685-691.
47. Ribeiro EE, Silva LA, Carneirt J, et al. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 1993;22:376-381.
48. Verheugt F. Primary angioplasty for acute myocardial infarction: Is the balloon half full or half empty? Lancet 1996;347:1276-1277.
49. Every NR, Parsons LS, Hlatky M, Weaver WD. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med 1996;335:1253-1260.
50. Walter H, Neumann FJ, Richardt G, et al. Antiplatelet vs. anticoagulation treatment after intracoronary PalmazSchatz stent placement in acute myocardial infarction. A prospective randomized trial. J Am Coll Cardiol 1996; 27:279A.
51. Lefevre T, Morice MC, Karrillon G, Aubry P, Zemour G, Valeix B. Coronary stenting during acute myocardial infarction. Results from the stent without Coumadin French registry. J Am Coll Cardiol 1996;27:69A.
52. LeMay MR, Labinaz M, Beanlands RSB, et al. Intracoronary stenting in the setting of myocardial infarction. J Am Coll Cardiol 1996;27:69A.
53. Monassier JP, Elias J, Meyer P, Morice MC, Royer T, Cribier A. STENTIM I: The French registry of stenting at acute myocardial infarction. J Am Coll Cardiol 1996; 27:68A.
54. Steinhubl SR, Moliterno DJ, Teirstein PS, et al. Stenting for acute myocardial infarction: The early United States multicenter experience. J Am Coll Cardiol 1996;27:279.
55. LATE Study Group. Late assessment of thrombolytic efficacy with alteplase 6-24 hours after the onset of acute myocardial infarction. Lancet 1993;342:759-766.
56. White HD. Thrombolytic therapy for patients with myocardial infarction presenting after six hours. Lancet 1992; 340:221-222.
57. Siu SC, Nirdorf SM, Galambos GS, Weyman AE, Picard MH. The effect of late patency of the infarct related artery on the left ventricular morphology and regional function after thrombolysis. Am Heart J 1992;124:265-272.
58. Sager PT, Perlmutter RA, Rosenfeld LE, McPherson CA, Wackers FJ, Batsford WP. Electrophysiologic effects of thrombolytic therapy in patients with a transmural anterior MI complicated by left ventricular aneurysm formation. J Am Coll Cardiol 1988;12:19-24.
59. Gibson CM, Cannon CP, Daley WL, et al. The TIMI frame count: A quantitative method of assessing coronary artery flow. Circulation 1996;93:879-888.
60. Ross AM, Neuhaus KL, Ellis SG. Frequent lack of concordance among core laboratories in assessing TIMI flow grade after reperfusion therapy. Circulation 1995;92:3452.
61. Uren NG, Crake T, Lefroy DC, DeSilva R, Davies GJ, Maseri A. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med 1994;331:222-227.
62. Wyatt HL, Forrester JS, Luz PL, Diamond G A, Chagrasulis R, Swan HJC. Functional abnormalities in nonoccluded regions of myocardium after experimental coronary occlusion. Am J Cardiol 1976;37:366-372.
63. Corday E, Kaplan L, Brasch J, et al. Consequences of coronary arterial occlusion on remote myocardium: Effects of occlusion and reperfusion. Am J Cardiol 1975;36:385-392.
64. Vikhert AM, Cherpachenko NM. Changes in metabolism of undamaged sections of myocardium following infarction. CircRes 1974;34:182-191.
65. Marjorie HJ, Debets JM, Snoeckx LH, Daeman MJ, Smits JF. Time related normalization of maximal coronary flow in isolated perfused hearts of rats with myocardial infarction. Circulation 1996;93:349-355.
66. Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992;85:1699-1705.
67. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the no reflow phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996;93:223-228.
68. Kloner RA, Ganote CE, Jennings RB. The "no reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974;54:1496-1508.
69. Krug A, Du Mesnil de Rochemont W, Korb G. Blood supply to the myocardium after temporary coronary occlusion. Circ Res 1966;19:57-62.
70. Humphrey SM, Gavin JB, Herdson PB. The relationship of ischemic contracture to vascular reperfusion in the isolated rat heart. J Mol Cell Cardiol 1980;12:1397-1406.
71. Forman MB, Puett DW, Virmani R. Endothelial and myocardial injury during ischemia and reperfusion. Pathogenesis and therapeutic implications. J Am Coll Cardiol 1989; 13:450-459.
72. Golino P, Ashton JH, Buja M, et al. Local platelet activation causes vasoconstriction of large epicardial arteries in vivo: Thromboxane A2 and serotonin are possible mediators. Circulation 1989;79:154-166.
73. Engler RL, Schmid-Schonbein GW, Pavelec RS. Leucocyte capillary plugging in myocardial ischemia and reperfusion in dog. Am J Pathol 1983;111:98-111.
74. Grech ED, Dodd NJ, Jackson MJ, Morrison WL, Faragher EB, Ramsdole DR. Evidence for free radical generation after primary percutaneous transluminal coronary angioplasty recanalization in acute myocardial infarction. Am J Cardiol 1996;77:122-127.
75. Przyklenk K, Kloner RA. "Reperfusion injury" by oxygenderived free radicals? Effect of superoxide dismutase plus catalase given at the time of reperfusion on myocardial infarct size, contractile coronary microvasculature, and regional myocardial blood flow. Circ Res 1989;86:86-96.
76. Olafsson B, Forman MB, Puett DW, Pou A, Gates CU, Friesinger GC, Virmani R. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: Importance of the endothelium and the "no reflow" phenomenon. Circulation 1987;76:1135-1145.
77. Campbell CA, Kloner RA, Alker KJ, Braunwald E. Effect of verapamil on infarct size in dogs subjected to coronary artery occlusion with transient reperfusion. J Am Coll Cardiol 1986;8:1169-1174.
78. Piana RN, Paik GY, Cohen DJ, Moscucci M, Kugelmass AD, Gibson CM, Bairn DS. Intracoronary verapamil for "no reflow" following PTCA. Circulation 1993;88:I587.
79. Rizzo MJ, Cannon CP, McLean C, et al. Relationship between timing of vessel opening after thrombolysis and flow at 90 minutes. Circulation 1996;94:I440.
80. Glanz A, Primer of Bio statistics, 3rd ed. New York: McGraw Hill, 1992;6.
81. Dotani I, Dodge TJ, Goel M, et al. New techniques in the angiographie analysis of coronary flow. J. Intervent Cardiol 1996;9:429-444.
82. Gibson CM, Cannon CP, Marble SJ, et al. for the TIMI 4 Investigators. The corrected TIMI frame count (CTFC) predicts clinical outcomes in acute MI. Circulation 1996;94:I441.
83. Gibson CM, Goel M, Dotani I, et al. for the RESTORE Investigators. The post-PTCA TIMI frame count and mortality in RESTORE. Circulation 1996;94:I85.